DAWN Stock Analysis: Buy, Sell, or Hold?
DAWN - Day One Biopharmaceuticals, Inc. Common Stock
$21.45
0.03 (0.14%)
▲
5d:
+0.23%
30d:
+66.67%
90d:
+130.15%
BUY
MODERATE Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: May 05, 2026
28d
Smart Money Accumulation
DAWN is down 5.5% this week, but smart money is accumulating calls. Top strike: $11 2026-04-17 with 16,577 OI. Call ratio: 100% View Scanner →
Strength: 7.7/10
Get Alerted When DAWN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: DAWN shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: DAWN shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: DAWN is currently trading at $21.45, which is considered slightly high relative to its 30-day fair value range of $13.57 to $22.91. From a valuation perspective, the stock is trading at a discount (Forward PE: -502.3) compared to its historical average (73.7). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, DAWN is in a strong uptrend. The price is currently testing key support at $21.30. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, DAWN is in a strong uptrend. The price is currently testing key support at $21.30. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Fair Price Range
$13.57 -
$22.91
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
65.2%
Protect Your Profits
DAWN is technically overbought (RSI 81). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($21.50)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Fair Price Analysis
30-Day Fair Range
$13.57 -
$22.91
Current vs Fair Value
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$21.30
Resistance Level
$21.47
Current Trend
Strong Uptrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-502.34
Wall Street Target
$21.50
(+0.2%)
Revenue Growth (YoY)
83.9%
Profit Margin
-67.8%
PE vs Historical
-502.3 vs 73.7
CHEAP
Share & Embed Analysis
Last updated: April 06, 2026 5:12 AM ET
Data refreshes hourly during market hours. Next update: 6:12 AM
Data refreshes hourly during market hours. Next update: 6:12 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DAWN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
9
Sells
Net
INSIDERS SELLING
Recent Transactions
Charles N York II
SELL
6065 shares
2026-02-17
Jeremy Bender
SELL
15459 shares
2026-02-17
Lauren Merendino
SELL
5814 shares
2026-02-17
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$25 | 53 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$411 | 52 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$111 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$8 | 53 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$33 | 61 BUY |
Advanced DAWN Option Strategies
Professional options setups generated by AI based on today's DAWN price and gamma walls.
